title: Effects of urine pH modification on pharmacokinetics of phenobarbital in healthy dogs.
abstract: Although pH modification is one of the effective strategies for dissolving or preventing uroliths, little is known about its effects on the pharmacokinetics of phenobarbital in dogs. Five spayed, female Beagles were fed with a twice-daily diet that included potassium citrate and ammonium chloride for urine alkalinization and acidification, respectively. After a stabilizing period of 7 days, a single clinical dose of phenobarbital (3 mg/kg) was orally administered, and time-course changes in its serum and urine concentrations were determined by high-performance liquid chromatography. Total amounts of unchanged phenobarbital excreted into urine for 216 h were decreased by urine acidification and increased by urine alkalinization. The elimination half-life of serum phenobarbital in dogs with urine alkalinization was shortened and Cl(R) increased when compared with dogs with urine acidification. Other pharmacokinetic parameters, including C(max), T(max), AUC(0-216), Cl/F, and A(e0-216) were not changed by modification of the urine pH. These results suggest that the pH of urine is likely to be a determinant of the pharmacokinetics, especially urine excretion rate, of a clinical dose of oral phenobarbital. It is possible that the serum concentration of phenobarbital might be altered when a pH modifying-diet is administered for the purpose of dissolving or preventing uroliths.
authors.affiliation: Department of Pharmacology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Fukunaga
authors.forename: M
authors.initials: M
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Muto
authors.forename: K
authors.initials: K
authors.lastname: Mishima
authors.forename: M
authors.initials: M
authors.lastname: Fujiwara
authors.forename: K
authors.initials: K
authors.lastname: Orito
mesh_terms: D000284:Administration, Oral; D000643:Ammonium Chloride / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D005260:Female; D006207:Half-Life; D006863:Hydrogen-Ion Concentration; D016014:Linear Models; D008657:Metabolic Clearance Rate; D010634:Phenobarbital / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D019357:Potassium Citrate / Q000494:pharmacology; D014556:Urine / Q000737:chemistry
chemical_list: D000927:Anticonvulsants; D000643:Ammonium Chloride; D019357:Potassium Citrate; D010634:Phenobarbital